Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 15;16(8):3481–3495. doi: 10.4251/wjgo.v16.i8.3481

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

An example of follow-up medical record of camrelizumab plus apatinib and hepatic artery infusion chemotherapy treatment in hepatocellular carcinoma patients with tumor thrombus of right inferior portal vein. A 48-year-old male patient with hepatocellular carcinoma (arrow) were examined [the maximum diameter, 13.1 cm; location in S4/8; alpha-fetoprotein (AFP), > 121000 ng/mL] by contrast enhanced magnetic resonance imaging scanning on July 2021. A-C: Preoperative scan [T1WI portal phase]; D-F: After two-cycle camrelizumab plus apatinib and hepatic artery infusion chemotherapy (TRIPLET), the tumor (arrow) has shrunk (the maximum diameter, 7.7 cm; AFP, 10616.0 ng/mL) (T1WI portal phase); G-I: After four-cycle TRIPLET, the tumor (arrow) has shrunk significantly (the maximum diameter, 7.0 cm; AFP, 6183.00 ng/mL) (T1WI portal phase).